Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04882878 · ClinicalTrials.gov registry record · Phase 2
A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
NCT04882878 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 228 participants.
The verdict
NCT04882878, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).
Interventions
- OTHER Placebo
- DRUG Nipocalimab
- DRUG Standard-of-care treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2021-08-20 |
| Est. Completion | 2024-12-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04882878
The ClinicalTrials.gov registry entry for NCT04882878 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04882878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04882878 about?
NCT04882878 is a clinical study titled "A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus". The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).
What is the current status of trial NCT04882878?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2021-08-20. Estimated completion is 2024-12-26.
What interventions are being tested in trial NCT04882878?
The interventions under investigation include: Placebo (OTHER), Nipocalimab (DRUG), Standard-of-care treatment (DRUG).
Who is sponsoring clinical trial NCT04882878?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.